Freestone Grove Partners LP Invests $855,000 in Prestige Consumer Healthcare Inc. $PBH

Freestone Grove Partners LP acquired a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH) in the second quarter, Holdings Channel.com reports. The institutional investor acquired 18,079 shares of the company’s stock, valued at approximately $855,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in PBH. Lido Advisors LLC raised its stake in Prestige Consumer Healthcare by 5.4% during the 4th quarter. Lido Advisors LLC now owns 3,778 shares of the company’s stock valued at $235,000 after acquiring an additional 192 shares in the last quarter. Cerity Partners LLC grew its stake in shares of Prestige Consumer Healthcare by 5.9% in the second quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock worth $310,000 after purchasing an additional 218 shares in the last quarter. UMB Bank n.a. grew its stake in shares of Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after purchasing an additional 219 shares in the last quarter. Versant Capital Management Inc increased its holdings in shares of Prestige Consumer Healthcare by 47.9% during the second quarter. Versant Capital Management Inc now owns 726 shares of the company’s stock valued at $34,000 after purchasing an additional 235 shares during the period. Finally, Caitong International Asset Management Co. Ltd increased its holdings in shares of Prestige Consumer Healthcare by 69.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after purchasing an additional 236 shares during the period. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare News Roundup

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Attractive value profile: A Zacks comparison of PBH and Stryker (SYK) highlights the value-investing case for Prestige Consumer Healthcare. PBH’s lower earnings multiple and defensive consumer-healthcare portfolio could support investor interest, although the comparison does not guarantee that PBH is the superior investment. PBH vs. SYK: Which Stock Is the Better Value Option?
• Positive Sentiment: Longer-term earnings growth: Zacks Research projects EPS of $4.55 for fiscal 2027, rising to $5.06 in fiscal 2028 and $5.25 in fiscal 2029. The forecasts imply improving earnings power and provide a potential catalyst if the company delivers.
• Neutral Sentiment: Quarterly estimates remain steady: Zacks forecasts EPS of $1.06 for fiscal Q2 2027, $1.22 for Q3 and $1.30 for Q4, followed by estimates of $1.14, $1.19, $1.38 and $1.35 for fiscal 2028’s quarters. These projections indicate expectations for consistent profitability rather than a near-term earnings surprise.
• Negative Sentiment: Analyst stance is cautious: Zacks Research maintains a “Hold” rating, and its fiscal 2027 EPS forecast of $4.55 is essentially in line with the $4.56 consensus estimate. That suggests the expected earnings growth is largely recognized in current expectations, limiting an immediate upgrade catalyst.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on PBH shares. Zacks Research upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, August 10th. Weiss Ratings lowered shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, June 25th. Canaccord Genuity Group lowered their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Finally, Oppenheimer downgraded shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Prestige Consumer Healthcare presently has an average rating of “Hold” and a consensus target price of $70.75.

Prestige Consumer Healthcare Stock Performance

PBH opened at $52.48 on Friday. The business has a 50 day moving average price of $50.22 and a two-hundred day moving average price of $54.62. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99. The company has a market capitalization of $2.49 billion, a price-to-earnings ratio of 14.70, a price-to-earnings-growth ratio of 1.64 and a beta of 0.34. Prestige Consumer Healthcare Inc. has a 1-year low of $42.62 and a 1-year high of $71.07.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The company had revenue of $265.71 million for the quarter, compared to analysts’ expectations of $253.02 million. During the same period last year, the firm earned $0.90 EPS. The firm’s revenue for the quarter was up 6.5% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Research analysts predict that Prestige Consumer Healthcare Inc. will post 4.56 EPS for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).